| Entry |
|
|---|
| Name |
Tivozanib hydrochloride (USAN);
Tivozanib hydrochloride monohydrate;
Fotivda (TN) |
|---|
| Product |
|
|---|
| Formula |
C22H19ClN4O5. HCl. H2O
|
|---|
| Exact mass |
508.0916
|
|---|
| Mol weight |
509.3393
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03203 VEGFR inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG01375): | D10190<US> |
|
|---|
| Efficacy |
Antineoplastic, Angiogenesis inhibitor, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Renal cell carcinoma [DS: H00021] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
L01EK03 Tivozanib
D10190 Tivozanib hydrochloride (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Tivozanib
D10190 Tivozanib hydrochloride (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03203 VEGFR inhibitor
DG01375 Tivozanib
D10190 Tivozanib hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01375 Tivozanib
D10190 Tivozanib hydrochloride
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFRB
D10190 Tivozanib hydrochloride (USAN) <US>
KIT (CD117)
D10190 Tivozanib hydrochloride (USAN) <US>
VEGFR family
VEGFR1 (FLT1)
D10190 Tivozanib hydrochloride (USAN) <US>
VEGFR2 (KDR)
D10190 Tivozanib hydrochloride (USAN) <US>
VEGFR3 (FLT4)
D10190 Tivozanib hydrochloride (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10190
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10190
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10190
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10190
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03203 VEGFR inhibitor
DG01375 Tivozanib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01375 Tivozanib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 34
1 C8y C 17.0800 -19.3200
2 C8y C 17.0800 -20.7200
3 C8x C 18.3400 -21.4200
4 C8y C 19.5300 -20.7200
5 C8y C 19.5300 -19.3200
6 C8x C 18.3400 -18.6200
7 C8y C 20.7200 -21.4200
8 C8x C 21.9800 -20.7200
9 C8x C 21.9800 -19.3200
10 N5x N 20.7200 -18.6200
11 O2a O 20.7200 -22.8200
12 C8y C 21.9800 -23.5200
13 O2a O 15.8900 -18.6200
14 C1a C 14.7000 -19.2500
15 O2a O 15.8900 -21.4200
16 C1a C 14.7000 -20.7200
17 C8x C 21.9800 -24.9200
18 C8y C 23.1700 -25.6200
19 C8y C 24.3600 -24.9200
20 C8x C 24.3600 -23.5200
21 C8x C 23.1700 -22.8200
22 N1b N 25.6200 -25.6200
23 C5a C 26.8100 -24.9200
24 N1b N 28.0000 -25.6200
25 C8y C 29.1900 -24.9200
26 O5a O 26.8100 -23.5200
27 X Cl 23.1700 -27.0200
28 C8x C 29.1900 -23.5200
29 N5x N 30.5200 -25.3400
30 O2x O 31.3600 -24.2200
31 C8y C 30.5200 -23.0300
32 C1a C 30.9400 -21.7700
33 X Cl 26.1800 -18.8300
34 O0 O 29.4000 -18.8300
BOND 35
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 2
7 4 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 5 10 1
12 7 11 1
13 11 12 1
14 1 13 1
15 13 14 1
16 2 15 1
17 15 16 1
18 12 17 2
19 17 18 1
20 18 19 2
21 19 20 1
22 20 21 2
23 12 21 1
24 19 22 1
25 22 23 1
26 23 24 1
27 24 25 1
28 23 26 2
29 18 27 1
30 25 28 1
31 25 29 2
32 29 30 1
33 30 31 1
34 28 31 2
35 31 32 1
|
|---|
